Literature DB >> 12211438

Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells.

Hisatomo Kondo1, Jun Guo, F Richard Bringhurst.   

Abstract

Parathyroid hormone (PTH) is a major regulator of osteoclast formation and activation, effects that are associated with reciprocal up- and down-regulation of RANKL and osteoprotegerin (OPG), respectively. The roles of specific downstream signals generated by the activated PTH/PTH-related protein (PTHrP) receptor (PTH1R), such as cyclic adenosine monophosphate/protein kinase A (cAMP/PKA) and phospholipase C/protein kinase C (PLC/PKC), in controlling RANKL and OPG expression and osteoclastogenesis remain uncertain. In MS1 conditionally transformed clonal murine marrow stromal cells, which support PTH-induced osteoclast formation from cocultured normal spleen cells, PTH(1-34) increased RANKL and macrophage colony-stimulating factor (M-CSF) mRNA expression and decreased that of OPG when present continuously for 7-20 days at 37 degrees C in the presence of dexamethasone (Dex). In cells precultured for 7 days and then treated with PTH(1-34), similar reciprocal regulation of RANKL and OPG occurred, maximally at 6-24 h, that was of greater amplitude than the changes induced by chronic (7-10 days) PTH exposure. These acute effects of PTH(1-34) were mimicked by PKA stimulators (8-bromoadenosine [8Br]-cAMP or forskolin [FSK]), blocked by the PKA inhibitor Rp-cAMPs but unaffected by the PKC inhibitor GF109203X. Amino-truncated PTH(1-34) analogs PTH(5-34) and PTH(7-34) neither increased cAMP production in MS1 cells nor regulated RANKL or OPG mRNA. Reciprocal RANKL/OPG mRNA regulation was induced in MS1 cells by PTH(3-34) but only at high concentrations that also increased cAMP. The highly PKA-selective PTH analog [Gly1,Arg19]human PTH(1-28) exerted effects similar to PTH(1-34) on RANKL and OPG mRNAs and on osteoclast formation, both in MS1/spleen cell cocultures and in normal murine bone marrow cultures. The direct PKC stimulator 12-O-tetradecanoylphorbol-13-acetate (PMA) did not induce RANKL mRNA in MS1 cells, but it did up-regulate OPG mRNA and also antagonized osteoclast formation induced by PTH(1-34) in both MS1/spleen cocultures and normal bone marrow cultures. Thus, cAMP/PKA signaling via the PTH1R is the primary mechanism for controlling RANKL-dependent osteoclastogenesis, although direct PKC activation may negatively regulate this effect of PTH by inducing expression of OPG.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12211438     DOI: 10.1359/jbmr.2002.17.9.1667

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  44 in total

1.  Caffeine inhibits the viability and osteogenic differentiation of rat bone marrow-derived mesenchymal stromal cells.

Authors:  Y Zhou; X X Guan; Z L Zhu; J Guo; Y C Huang; W W Hou; H Y Yu
Journal:  Br J Pharmacol       Date:  2010-12       Impact factor: 8.739

2.  Control of the SOST bone enhancer by PTH using MEF2 transcription factors.

Authors:  Olivier Leupin; Ina Kramer; Nicole M Collette; Gabriela G Loots; François Natt; Michaela Kneissel; Hansjoerg Keller
Journal:  J Bone Miner Res       Date:  2007-12       Impact factor: 6.741

3.  Protein kinase-A-dependent osteoprotegerin production on interleukin-1 stimulation in human gingival fibroblasts is distinct from periodontal ligament fibroblasts.

Authors:  D Hormdee; T Nagasawa; M Kiji; R Yashiro; H Kobayashi; G Koshy; K Noguchi; H Nitta; I Ishikawa
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

4.  Activation of EPAC1/2 is essential for osteoclast formation by modulating NFκB nuclear translocation and actin cytoskeleton rearrangements.

Authors:  Aránzazu Mediero; Miguel Perez-Aso; Bruce N Cronstein
Journal:  FASEB J       Date:  2014-08-13       Impact factor: 5.191

5.  Parathyroid hormone controls receptor activator of NF-kappaB ligand gene expression via a distant transcriptional enhancer.

Authors:  Qiang Fu; Stavros C Manolagas; Charles A O'Brien
Journal:  Mol Cell Biol       Date:  2006-09       Impact factor: 4.272

6.  Activation of receptor activator of NF-kappaB ligand gene expression by 1,25-dihydroxyvitamin D3 is mediated through multiple long-range enhancers.

Authors:  Sungtae Kim; Miwa Yamazaki; Lee A Zella; Nirupama K Shevde; J Wesley Pike
Journal:  Mol Cell Biol       Date:  2006-09       Impact factor: 4.272

7.  An enhancer 20 kilobases upstream of the human receptor activator of nuclear factor-kappaB ligand gene mediates dominant activation by 1,25-dihydroxyvitamin D3.

Authors:  Robert D Nerenz; Melissa L Martowicz; J Wesley Pike
Journal:  Mol Endocrinol       Date:  2008-01-17

Review 8.  Control of RANKL gene expression.

Authors:  Charles A O'Brien
Journal:  Bone       Date:  2009-08-27       Impact factor: 4.398

Review 9.  Targeting bone physiology for the treatment of metastatic prostate cancer.

Authors:  Karen A Autio; Michael J Morris
Journal:  Clin Adv Hematol Oncol       Date:  2013-03

10.  Rolipram, a phosphodiesterase 4 inhibitor, stimulates inducible cAMP early repressor expression in osteoblasts.

Authors:  Eun Sook Cho; Ja Heon Yu; Mi Sun Kim; Mijung Yim
Journal:  Yonsei Med J       Date:  2005-02-28       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.